What is it used for?
POLIVY in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater. POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after at least two prior therapies.POLIVY in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater. POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after at least two prior therapies.
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- polatuzumab vedotinpolatuzumab vedotin
- Form and strength
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 140 mg / 7.52 mL; INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 30 mg / 1.88 mLINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 140 mg / 7.52 mL; INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 30 mg / 1.88 mL
- Manufacturer / applicant
- GENENTECH, INC.GENENTECH, INC.
For injection: 30 mg/vial or 140 mg/vial of polatuzumab vedotin-piiq as a white to grayish-white lyophilized powder in a single-dose vial for reconstitution and further dilution.For injection: 30 mg/vial or 140 mg/vial of polatuzumab vedotin-piiq as a white to grayish-white lyophilized powder in a single-dose vial for reconstitution and further dilution.
Safety and clinical review
- Peripheral NeuropathyPeripheral Neuropathy
- Infusion-Related ReactionsInfusion-Related Reactions
- MyelosuppressionMyelosuppression
- Serious and Opportunistic InfectionsSerious and Opportunistic Infections
- Progressive Multifocal Leukoencephalopathy (PML)Progressive Multifocal Leukoencephalopathy (PML)
- Tumor Lysis SyndromeTumor Lysis Syndrome
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is POLIVY used for?
POLIVY in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater. POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after at least two prior therapies.POLIVY in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater. POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after at least two prior therapies.
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of POLIVY should I ask about?
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 140 mg / 7.52 mL; INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 30 mg / 1.88 mLINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 140 mg / 7.52 mL; INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 30 mg / 1.88 mL
Read the primary sourceWhat determines the price of POLIVY?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using POLIVY?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.